AnkeBio’s Class 1 Innovative Drug AK2024 Presents Core Data
at the AACR Annual Meeting 2026
March 23, 2026-Anhui Anke Biotechnology (Group) Co., Ltd. (AnkeBio) today announced that its independently developed Class 1 innovative drug, AK2024 injection, will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026. This marks another appearance by AnkeBio at a premier global oncology platform, demonstrating the company’s growing strength in innovative cancer drug development.
The AACR Annual Meeting is the world’s largest and most academically influential oncology conference, widely recognized as a bellwether for advances in basic and translational cancer research. Bringing together leading investigators, scientists, clinicians, and industry professionals, it serves as an essential global stage for unveiling cutting-edge cancer technologies and novel therapeutic candidates.
Human epidermal growth factor receptor 2 (HER2) is a well-established target in oncology, closely linked to the initiation, progression, invasion, and prognosis of multiple high-incidence malignancies, including breast and gastric cancers. AK2024 injection, a key asset in AnkeBio’s innovative pipeline, is a novel anti-HER2 monoclonal antibody. It selectively acts on a specific extracellular domain of HER2, with an antigen recognition epitope distinct from the binding sites of trastuzumab and pertuzumab, endowing it with a unique molecular structure and mechanistic advantage.
Preclinical in vitro and in vivo studies have shown that AK2024 inhibits the proliferation of HER2-overexpressing tumor cells and exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Moreover, AK2024 synergizes with trastuzumab and HER2-directed antibody-drug conjugates (ADCs), with an antitumor synergy effect superior to that of pertuzumab (Perjeta). These properties position AK2024 as a potentially optimal “Booster” for both trastuzumab and HER2-ADCs, offering a promising new approach for combination strategies against HER2-positive tumors. AK2024 injection has now advanced into a Phase I registrational clinical trial
